Hence, our findings not only reveal a molecular mechanism for the oncogenic function of BAP1 and the regulation of MYCN stability but also provide molecular rationale for the clinical exploration of novel strategies to combat NB in MYCN-amplified patients by targeting the deubiquitylase BAP1 (Fig. 6). Here, MYCN is linked to neuroblastoma.